Clinical trials: Renal Ischemia
Bleeding Disorder, Stroke, Ischemic
XIENCE 28 Global Study
XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of…
- Conditions
- Bleeding Disorder, Stroke, Ischemic, Stroke Hemorrhagic, Hematological Disease
- Trial name
- NCT03355742
- Testing
- XIENCE, DAPT
- Where
- 52 sites in Austria, Belgium and 11 more
- Volunteers
- 963 people
- Sponsor
- Abbott Medical Devices
Ischemia-Reperfusion Injury, Kidney Diseases
Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation
The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after solid organ transplantation. Reparixin is a novel, specific inhibitor of CXCL8.
- Trial name
- NCT00248040
- Testing
- Reparixin continuous infusion, reparixin intermittent infusion
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Dompé Farmaceutici S.p.A
Bleeding Disorder, Ischemic Stroke
XIENCE 28 USA Study
The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR)…
- Conditions
- Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases
- Trial name
- NCT03815175
- Testing
- XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 1,605 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Stenosis
Kidney Damage in Patients With Normal eGFR
This is a pilot study, randomized, double-blind, parallel group comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have normal eGFR.
- Trial name
- NCT01137786
- Testing
- Non ionic contrast media comparator
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Bracco Diagnostics, Inc
Kidney Diseases, Coronary Artery Disease
A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment
This study is intended to assess the safety and tolerance of regadenoson in subjects with renal impairment.
- Trial name
- NCT00863707
- Testing
- Regadenoson
- Where
- 41 sites in United States
- Volunteers
- 511 people
- Sponsor
- Astellas Pharma Inc
Renal Artery Obstruction, Hypertension, Renovascular
Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery
This was a Phase 2a prospective, single center, randomized, double-blind, placebo-controlled study designed to assess the efficacy, pharmacokinetics, safety and tolerability of IV elamipretide for reduction of reperfusion injury…
- Conditions
- Renal Artery Obstruction, Hypertension, Renovascular, Ischemia Reperfusion Injury
- Trial name
- EVOLVE (NCT01755858)
- Testing
- Bendavia
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Stealth BioTherapeutics Inc.
Coronary Artery Stenosis
Kidney Damage In Patients With Severe Fall In eGFR
This is a pilot study using a randomized, double blinded, comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI).
- Trial name
- NCT01136915
- Testing
- Iopamidol 370, Iodixanol 320
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Bracco Diagnostics, Inc
Coronary Artery Stenosis
Kidney Damage in Patients With Moderate Fall in eGFR
To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR
- Trial name
- NCT01136876
- Testing
- Iopamidol, Iodixanol-320
- Where
- 4 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- Bracco Diagnostics, Inc